6/O ADVERSE/O REACTIONS/O The/O following/O are/O discussed/O in/O more/O detail/O in/O other/O sections/O of/O the/O labeling/O :/O Hypertension/B-AdverseReaction ,/O Hypokalemia/B-AdverseReaction ,/O and/O Fluid/B-AdverseReaction Retention/I-AdverseReaction due/O to/O Mineralocorticoid/B-AdverseReaction Excess/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
Adrenocortical/B-AdverseReaction Insufficiency/I-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.2/O )/O ]/O ./O
Hepatotoxicity/B-AdverseReaction [/O seeWarnings/O and/O Precautions/O (/O 5.3/O )/O ]/O ./O
EXCERPT/O :/O The/O most/O common/O adverse/O reactions/O (/O 10/O %/O )/O are/O fatigue/B-AdverseReaction ,/O joint/B-AdverseReaction swelling/I-AdverseReaction or/O discomfort/O ,/O edema/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction and/O contusion/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O 20/O %/O )/O are/O anemia/B-AdverseReaction ,/O elevated/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O elevated/B-AdverseReaction AST/I-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O elevated/B-AdverseReaction ALT/I-AdverseReaction and/O hypokalemia/B-AdverseReaction ./O
(/O 6/O )/O To/O report/O SUSPECTED/O ADVERSE/O REACTIONS/O ,/O contact/O Janssen/O Biotech/O ,/O Inc./O at/O 1/O -/O 800/O -/O 526/O -/O 7736/O (/O 1/O -/O 800-JANSSEN/O )/O or/O FDA/O at/O 1/O -/O 800-FDA-1088/O or/O www.fda.gov/medwatch/O ./O
6.1/O Clinical/O Trial/O Experience/O Because/O clinical/O trials/O are/O conducted/O under/O widely/O varying/O conditions/O ,/O adverse/O reaction/O rates/O observed/O in/O the/O clinical/O trials/O of/O a/O drug/O can/O not/O be/O directly/O compared/O to/O rates/O in/O the/O clinical/O trials/O of/O another/O drug/O and/O may/O not/O reflect/O the/O rates/O observed/O in/O clinical/O practice/O ./O
Two/O randomized/O placebo/O -/O controlled/O ,/O multicenter/O clinical/O trials/O enrolled/O patients/O who/O had/O metastatic/O castration/O -/O resistant/O prostate/O cancer/O who/O were/O using/O a/O gonadotropin/O -/O releasing/O hormone/O (/O GnRH/O )/O agonist/O or/O were/O previously/O treated/O with/O orchiectomy/O ./O
In/O both/O Study/O 1/O and/O Study/O 2/O ZYTIGA/O was/O administered/O at/O a/O dose/O of/O 1,000/O mg/O daily/O in/O combination/O with/O prednisone/O 5/O mg/O twice/O daily/O in/O the/O active/O treatment/O arms/O ./O
Placebo/O plus/O prednisone/O 5/O mg/O twice/O daily/O was/O given/O to/O control/O patients/O ./O
The/O most/O common/O adverse/O drug/O reactions/O (/O 10/O %/O )/O reported/O in/O the/O two/O randomized/O clinical/O trials/O that/O occurred/O more/O commonly/O (/O 2/O %/O )/O in/O the/O abiraterone/O acetate/O arm/O were/O fatigue/B-AdverseReaction ,/O joint/B-AdverseReaction swelling/I-AdverseReaction or/O discomfort/O ,/O edema/B-AdverseReaction ,/O hot/B-AdverseReaction flush/I-AdverseReaction ,/O diarrhea/B-AdverseReaction ,/O vomiting/B-AdverseReaction ,/O cough/B-AdverseReaction ,/O hypertension/B-AdverseReaction ,/O dyspnea/B-AdverseReaction ,/O urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction and/O contusion/B-AdverseReaction ./O
The/O most/O common/O laboratory/O abnormalities/O (/O 20/O %/O )/O reported/O in/O the/O two/O randomized/O clinical/O trials/O that/O occurred/O more/O commonly/O (/O 2/O %/O )/O in/O the/O abiraterone/O acetate/O arm/O were/O anemia/B-AdverseReaction ,/O elevated/B-AdverseReaction alkaline/I-AdverseReaction phosphatase/I-AdverseReaction ,/O hypertriglyceridemia/B-AdverseReaction ,/O lymphopenia/B-AdverseReaction ,/O hypercholesterolemia/B-AdverseReaction ,/O hyperglycemia/B-AdverseReaction ,/O elevated/B-AdverseReaction AST/I-AdverseReaction ,/O hypophosphatemia/B-AdverseReaction ,/O elevated/B-AdverseReaction ALT/I-AdverseReaction and/O hypokalemia/B-AdverseReaction ./O
Study/O 1/O :/O Metastatic/O CRPC/O Following/O Chemotherapy/O Study/O 1/O enrolled/O 1195/O patients/O with/O metastatic/O CRPC/O who/O had/O received/O prior/O docetaxel/O chemotherapy/O ./O
Patients/O were/O not/O eligible/O if/O AST/O and/or/O ALT/O 2.5/O ULN/O in/O the/O absence/O of/O liver/O metastases/O ./O
Patients/O with/O liver/O metastases/O were/O excluded/O if/O AST/O and/or/O ALT/O 5/O ULN/O ./O
Table/O 1/O shows/O adverse/O reactions/O on/O the/O ZYTIGA/O arm/O in/O Study/O 1/O that/O occurred/O with/O a/O 2/O %/O absolute/O increase/O in/O frequency/O compared/O to/O placebo/O or/O were/O events/O of/O special/O interest/O ./O
The/O median/O duration/O of/O treatment/O with/O ZYTIGA/O was/O 8/O months/O ./O
Table/O 1/O :/O Adverse/O Reactions/O due/O to/O ZYTIGA/O in/O Study/O 1/O ZYTIGA/O with/O Prednisone(N=791/O )/O Placebo/O with/O Prednisone(N=394/O )/O System/O Organ/O Class/O Adverse/O reaction/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Joint/B-AdverseReaction swelling/I-AdverseReaction discomfort/O 29.5/O 4.2/O 23.4/O 4.1/O Muscle/B-AdverseReaction discomfort/I-AdverseReaction 26.2/O 3.0/O 23.1/O 2.3/O General/O disorders/O Edema/B-AdverseReaction 26.7/O 1.9/O 18.3/O 0.8/O Vascular/O disorders/O Hot/B-AdverseReaction flush/I-AdverseReaction 19.0/O 0.3/O 16.8/O 0.3/O Hypertension/B-AdverseReaction 8.5/O 1.3/O 6.9/O 0.3/O Gastrointestinal/O disorders/O Diarrhea/B-AdverseReaction 17.6/O 0.6/O 13.5/O 1.3/O Dyspepsia/B-AdverseReaction 6.1/O 0/O 3.3/O 0/O Infections/O and/O infestations/O Urinary/B-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 11.5/O 2.1/O 7.1/O 0.5/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 5.4/O 0/O 2.5/O 0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 10.6/O 0/O 7.6/O 0/O Renal/O and/O urinary/O disorders/O Urinary/B-AdverseReaction frequency/I-AdverseReaction 7.2/O 0.3/O 5.1/O 0.3/O Nocturia/B-AdverseReaction 6.2/O 0/O 4.1/O 0/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Fractures/B-AdverseReaction 5.9/O 1.4/O 2.3/O 0/O Cardiac/O disorders/O Arrhythmia/B-AdverseReaction 7.2/O 1.1/O 4.6/O 1.0/O Chest/B-AdverseReaction pain/I-AdverseReaction or/O chest/B-AdverseReaction discomfort/I-AdverseReaction 3.8/O 0.5/O 2.8/O 0/O Cardiac/B-AdverseReaction failure/I-AdverseReaction 2.3/O 1.9/O 1.0/O 0.3/O Table/O 2/O shows/O laboratory/O abnormalities/O of/O interest/O from/O Study/O 1/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O low/B-AdverseReaction serum/I-AdverseReaction phosphorus/I-AdverseReaction (/O 7/O %/O )/O and/O low/B-AdverseReaction potassium/I-AdverseReaction (/O 5/O %/O )/O occurred/O at/O a/O greater/O than/O or/O equal/O to/O 5/O %/O rate/O in/O the/O ZYTIGA/O arm/O ./O
Table/O 2/O :/O Laboratory/O Abnormalities/O of/O Interest/O in/O Study/O 1/O Abiraterone/O (/O N=791/O )/O Placebo/O (/O N=394/O )/O Laboratory/O Abnormality/O All/O Grades/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O All/O Grades/O (/O %/O )/O Grade/O 3/O -/O 4/O (/O %/O )/O Hypertriglyceridemia/B-AdverseReaction 62.5/O 0.4/O 53.0/O 0/O High/B-AdverseReaction AST/I-AdverseReaction 30.6/O 2.1/O 36.3/O 1.5/O Hypokalemia/B-AdverseReaction 28.3/O 5.3/O 19.8/O 1.0/O Hypophosphatemia/B-AdverseReaction 23.8/O 7.2/O 15.7/O 5.8/O High/B-AdverseReaction ALT/I-AdverseReaction 11.1/O 1.4/O 10.4/O 0.8/O High/B-AdverseReaction Total/I-AdverseReaction Bilirubin/I-AdverseReaction 6.6/O 0.1/O 4.6/O 0/O Study/O 2/O :/O Metastatic/O CRPC/O Prior/O to/O Chemotherapy/O Study/O 2/O enrolled/O 1088/O patients/O with/O metastatic/O CRPC/O who/O had/O not/O received/O prior/O cytotoxic/O chemotherapy/O ./O
Patients/O were/O ineligible/O if/O AST/O and/or/O ALT/O 2.5/O ULN/O and/O patients/O were/O excluded/O if/O they/O had/O liver/O metastases/O ./O
Table/O 3/O shows/O adverse/O reactions/O on/O the/O ZYTIGA/O arm/O in/O Study/O 2/O that/O occurred/O with/O a/O 2/O %/O absolute/O increase/O in/O frequency/O compared/O to/O placebo/O ./O
The/O median/O duration/O of/O treatment/O with/O ZYTIGA/O was/O 13.8/O months/O ./O
Table/O 3/O :/O Adverse/O Reactions/O in/O 5/O %/O of/O Patients/O on/O the/O ZYTIGA/O Arm/O in/O Study/O 2/O ZYTIGA/O with/O Prednisone/O (/O N=542/O )/O Placebo/O with/O Prednisone/O (/O N=540/O )/O System/O Organ/O Class/O Adverse/O reaction/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O All/O Grades%/O Grade/O 3/O -/O 4/O %/O General/O disorders/O Fatigue/B-AdverseReaction 39.1/O 2.2/O 34.3/O 1.7/O Edema/B-AdverseReaction 25.1/O 0.4/O 20.7/O 1.1/O Pyrexia/B-AdverseReaction 8.7/O 0.6/O 5.9/O 0.2/O Musculoskeletal/O and/O connective/O tissue/O disorders/O Joint/B-AdverseReaction swelling/I-AdverseReaction discomfort/O 30.3/O 2.0/O 25.2/O 2.0/O Groin/B-AdverseReaction pain/I-AdverseReaction 6.6/O 0.4/O 4.1/O 0.7/O Gastrointestinal/O disorders/O Constipation/B-AdverseReaction 23.1/O 0.4/O 19.1/O 0.6/O Diarrhea/B-AdverseReaction 21.6/O 0.9/O 17.8/O 0.9/O Dyspepsia/B-AdverseReaction 11.1/O 0.0/O 5.0/O 0.2/O Vascular/O disorders/O Hot/B-AdverseReaction flush/I-AdverseReaction 22.3/O 0.2/O 18.1/O 0.0/O Hypertension/B-AdverseReaction 21.6/O 3.9/O 13.1/O 3.0/O Respiratory/O ,/O thoracic/O and/O mediastinal/O disorders/O Cough/B-AdverseReaction 17.3/O 0.0/O 13.5/O 0.2/O Dyspnea/B-AdverseReaction 11.8/O 2.4/O 9.6/O 0.9/O Psychiatric/O disorders/O Insomnia/B-AdverseReaction 13.5/O 0.2/O 11.3/O 0.0/O Injury/O ,/O poisoning/O and/O procedural/O complications/O Contusion/B-AdverseReaction 13.3/O 0.0/O 9.1/O 0.0/O Falls/B-AdverseReaction 5.9/O 0.0/O 3.3/O 0.0/O Infections/O and/O infestations/O Upper/B-AdverseReaction respiratory/I-AdverseReaction tract/I-AdverseReaction infection/I-AdverseReaction 12.7/O 0.0/O 8.0/O 0.0/O Nasopharyngitis/B-AdverseReaction 10.7/O 0.0/O 8.1/O 0.0/O Renal/O and/O urinary/O disorders/O Hematuria/B-AdverseReaction 10.3/O 1.3/O 5.6/O 0.6/O Skin/O and/O subcutaneous/O tissue/O disorders/O Rash/B-AdverseReaction 8.1/O 0.0/O 3.7/O 0.0/O Table/O 4/O shows/O laboratory/O abnormalities/O that/O occurred/O in/O greater/O than/O 15/O %/O of/O patients/O ,/O and/O more/O frequently/O (/O 5/O %/O )/O in/O the/O ZYTIGA/O arm/O compared/O to/O placebo/O in/O Study/O 2/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O lymphopenia/B-AdverseReaction (/O 9/O %/O )/O ,/O hyperglycemia/B-AdverseReaction (/O 7/O %/O )/O and/O high/B-AdverseReaction alanine/I-AdverseReaction aminotransferase/I-AdverseReaction (/O 6/O %/O )/O occurred/O at/O a/O greater/O than/O 5/O %/O rate/O in/O the/O ZYTIGA/O arm/O ./O
Table/O 4/O :/O Laboratory/O Abnormalities/O in/O 15/O %/O of/O Patients/O in/O the/O ZYTIGA/O Arm/O of/O Study/O 2/O Abiraterone/O (/O N=542/O )/O Placebo/O (/O N=540/O )/O Laboratory/O Abnormality/O Grade/O 1/O -/O 4/O %/O Grade/O 3/O -/O 4/O %/O Grade/O 1/O -/O 4/O %/O Grade/O 3/O -/O 4/O %/O Hematology/O Lymphopenia/B-AdverseReaction 38.2/O 8.7/O 31.7/O 7.4/O Chemistry/O Hyperglycemia/B-AdverseReaction 56.6/O 6.5/O 50.9/O 5.2/O High/B-AdverseReaction ALT/I-AdverseReaction 41.9/O 6.1/O 29.1/O 0.7/O High/B-AdverseReaction AST/I-AdverseReaction 37.3/O 3.1/O 28.7/O 1.1/O Hypernatremia/B-AdverseReaction 32.8/O 0.4/O 25.0/O 0.2/O Hypokalemia/B-AdverseReaction 17.2/O 2.8/O 10.2/O 1.7/O Cardiovascular/O Adverse/O Reactions/O :/O In/O the/O combined/O data/O for/O studies/O 1/O and/O 2/O ,/O cardiac/B-AdverseReaction failure/I-AdverseReaction occurred/O more/O commonly/O in/O patients/O treated/O with/O ZYTIGA/O compared/O to/O patients/O on/O the/O placebo/O arm/O (/O 2.1/O %/O versus/O 0.7/O %/O )/O ./O
Grade/B-Severity 3/I-Severity -/O 4/O cardiac/B-AdverseReaction failure/I-AdverseReaction occurred/O in/O 1.6/O %/O of/O patients/O taking/O ZYTIGA/O and/O led/O to/O 5/O treatment/O discontinuations/O and/O 2/O deaths/B-AdverseReaction ./O
Grade/B-Severity 3/I-Severity -/O 4/O cardiac/B-AdverseReaction failure/I-AdverseReaction occurred/O in/O 0.2/O %/O of/O patients/O taking/O placebo/B-Factor ./O
There/O were/O no/O treatment/O discontinuations/O and/O one/O death/B-AdverseReaction due/O to/O cardiac/B-AdverseReaction failure/I-AdverseReaction in/O the/O placebo/B-Factor group/O ./O
In/O Study/O 1/O and/O 2/O ,/O the/O majority/O of/O arrhythmias/B-AdverseReaction were/O grade/B-Severity 1/I-Severity or/O 2/O ./O
There/O was/O one/O death/B-AdverseReaction associated/O with/O arrhythmia/B-AdverseReaction and/O one/O patient/O with/O sudden/B-AdverseReaction death/I-AdverseReaction in/O the/O ZYTIGA/O arms/O and/O no/B-Negation deaths/B-AdverseReaction in/O the/O placebo/B-Factor arms/O ./O
There/O were/O 7/O (/O 0.5/O %/O )/O deaths/B-AdverseReaction due/O to/O cardiorespiratory/B-AdverseReaction arrest/I-AdverseReaction in/O the/O ZYTIGA/O arms/O and/O 3/O (/O 0.3/O %/O )/O deaths/B-AdverseReaction in/O the/O placebo/B-Factor arms/O ./O
Myocardial/B-AdverseReaction ischemia/I-AdverseReaction or/O myocardial/B-AdverseReaction infarction/I-AdverseReaction led/O to/O death/B-AdverseReaction in/O 3/O patients/O in/O the/O placebo/B-Factor arms/O and/O 2/O deaths/B-AdverseReaction in/O the/O ZYTIGA/O arms/O ./O
6.2/O Post/O Marketing/O Experience/O The/O following/O additional/O adverse/O reactions/O have/O been/O identified/O during/O post/O approval/O use/O of/O ZYTIGA/O ./O
Because/O these/O reactions/O are/O reported/O voluntarily/O from/O a/O population/O of/O uncertain/O size/O ,/O it/O is/O not/O always/O possible/O to/O reliably/O estimate/O their/O frequency/O or/O establish/O a/O causal/O relationship/O to/O drug/O exposure/O ./O
Respiratory/O ,/O Thoracic/O and/O Mediastinal/O Disorders/O :/O non/B-AdverseReaction -/I-AdverseReaction infectious/O pneumonitis/O ./O
Musculoskeletal/O and/O Connective/O Tissue/O Disorders/O :/O myopathy/B-AdverseReaction ,/O including/O rhabdomyolysis/B-AdverseReaction ./O
5/O WARNINGS/O AND/O PRECAUTIONS/O EXCERPT/O :/O Mineralocorticoid/B-AdverseReaction excess/I-AdverseReaction :/O Use/O ZYTIGA/O with/O caution/O in/O patients/O with/O a/O history/O of/O cardiovascular/O disease/O ./O
The/O safety/O of/O ZYTIGA/O in/O patients/O with/O LVEF/O 50/O %/O or/O NYHA/O Class/O III/O or/O IV/O heart/O failure/O in/O Study/O 1/O or/O LVEF/O 50/O %/O or/O NYHA/O Class/O II/O to/O IV/O heart/O failure/O in/O Study/O 2/O was/O not/O established/O ./O
Control/O hypertension/O and/O correct/O hypokalemia/O before/O treatment/O ./O
Monitor/O blood/O pressure/O ,/O serum/O potassium/O and/O symptoms/O of/O fluid/O retention/O at/O least/O monthly/O ./O
(/O 5.1/O )/O Adrenocortical/B-AdverseReaction insufficiency/I-AdverseReaction :/O Monitor/O for/O symptoms/O and/O signs/O of/O adrenocortical/O insufficiency/O ./O
Increased/O dosage/O of/O corticosteroids/O may/O be/O indicated/O before/O ,/O during/O and/O after/O stressful/O situations/O ./O
(/O 5.2/O )/O Hepatotoxicity/B-AdverseReaction :/O Increases/B-AdverseReaction in/I-AdverseReaction liver/I-AdverseReaction enzymes/I-AdverseReaction have/O led/O to/O drug/O interruption/O ,/O dose/O modification/O and/or/O discontinuation/O ./O
Monitor/O liver/O function/O and/O modify/O ,/O interrupt/O ,/O or/O discontinue/O ZYTIGA/O dosing/O as/O recommended/O ./O
(/O 5.3/O )/O 5.1/O Hypertension/O ,/O Hypokalemia/O and/O Fluid/O Retention/O Due/O to/O Mineralocorticoid/O Excess/O ZYTIGA/O may/B-Factor cause/O hypertension/B-AdverseReaction ,/O hypokalemia/B-AdverseReaction ,/O and/O fluid/B-AdverseReaction retention/I-AdverseReaction as/O a/O consequence/O of/O increased/B-AdverseReaction mineralocorticoid/I-AdverseReaction levels/I-AdverseReaction resulting/O from/O CYP17/O inhibition/O [/O seeClinical/O Pharmacology/O (/O 12.1/O )/O ]/O ./O
In/O the/O two/O randomized/O clinical/O trials/O ,/O grade/B-Severity 3/I-Severity to/I-Severity 4/I-Severity hypertension/B-AdverseReaction occurred/O in/O 2/O %/O of/O patients/O ,/O grade/B-Severity 3/I-Severity to/I-Severity 4/I-Severity hypokalemia/B-AdverseReaction in/O 4/O %/O of/O patients/O ,/O and/O grade/B-Severity 3/I-Severity to/I-Severity 4/I-Severity edema/B-AdverseReaction in/O 1/O %/O of/O patients/O treated/O with/O ZYTIGA/O [/O seeAdverse/O Reactions/O (/O 6/O )/O ]/O ./O
Co/O -/O administration/O of/O a/O corticosteroid/O suppresses/O adrenocorticotropic/O hormone/O (/O ACTH/O )/O drive/O ,/O resulting/O in/O a/O reduction/O in/O the/O incidence/O and/O severity/O of/O these/O adverse/O reactions/O ./O
Use/O caution/O when/O treating/O patients/O whose/O underlying/O medical/O conditions/O might/O be/O compromised/O by/O increases/O in/O blood/O pressure/O ,/O hypokalemia/O or/O fluid/O retention/O ,/O e.g./O ,/O those/O with/O heart/O failure/O ,/O recent/O myocardial/O infarction/O or/O ventricular/O arrhythmia/O ./O
Use/O ZYTIGA/O with/O caution/O in/O patients/O with/O a/O history/O of/O cardiovascular/O disease/O ./O
The/O safety/O of/O ZYTIGA/O in/O patients/O with/O left/O ventricular/O ejection/O fraction/O 50/O %/O or/O New/O York/O Heart/O Association/O (/O NYHA/O )/O Class/O III/O or/O IV/O heart/O failure/O (/O in/O Study/O 1/O )/O or/O NYHA/O Class/O II/O to/O IV/O heart/O failure/O (/O in/O Study/O 2/O )/O was/O not/O established/O because/O these/O patients/O were/O excluded/O from/O these/O randomized/O clinical/O trials/O [/O seeClinical/O Studies/O (/O 14/O )/O ]/O ./O
Monitor/O patients/O for/O hypertension/O ,/O hypokalemia/O ,/O and/O fluid/O retention/O at/O least/O once/O a/O month/O ./O
Control/O hypertension/O and/O correct/O hypokalemia/O before/O and/O during/O treatment/O with/O ZYTIGA/O ./O
5.2/O Adrenocortical/O Insufficiency/O Adrenal/B-AdverseReaction insufficiency/I-AdverseReaction occurred/O in/O the/O two/O randomized/O clinical/O studies/O in/O 0.5/O %/O of/O patients/O taking/O ZYTIGA/O and/O in/O 0.2/O %/O of/O patients/O taking/O placebo/O ./O
Adrenocortical/B-AdverseReaction insufficiency/I-AdverseReaction was/O reported/O in/O patients/O receiving/O ZYTIGA/O in/O combination/O with/O prednisone/O ,/O following/O interruption/O of/O daily/O steroids/O and/or/O with/O concurrent/O infection/O or/O stress/O ./O
Use/O caution/O and/O monitor/O for/O symptoms/O and/O signs/O of/O adrenocortical/O insufficiency/O ,/O particularly/O if/O patients/O are/O withdrawn/O from/O prednisone/O ,/O have/O prednisone/O dose/O reductions/O ,/O or/O experience/O unusual/O stress/O ./O
Symptoms/O and/O signs/O of/O adrenocortical/B-AdverseReaction insufficiency/I-AdverseReaction may/O be/O masked/O by/O adverse/O reactions/O associated/O with/O mineralocorticoid/B-AdverseReaction excess/I-AdverseReaction seen/O in/O patients/O treated/O with/O ZYTIGA/O ./O
If/O clinically/O indicated/O ,/O perform/O appropriate/O tests/O to/O confirm/O the/O diagnosis/O of/O adrenocortical/O insufficiency/O ./O
Increased/O dosage/O of/O corticosteroids/O may/O be/O indicated/O before/O ,/O during/O and/O after/O stressful/O situations/O [/O seeWarnings/O and/O Precautions/O (/O 5.1/O )/O ]/O ./O
5.3/O Hepatotoxicity/O In/O the/O two/O randomized/O clinical/O trials/O ,/O grade/B-Severity 3/I-Severity or/O 4/O ALT/O or/O AST/B-AdverseReaction increases/I-AdverseReaction (/O at/O least/O 5/O ULN/O )/O were/O reported/O in/O 4/O %/O of/O patients/O who/O received/O ZYTIGA/O ,/O typically/O during/O the/O first/O 3/O months/O after/O starting/O treatment/O ./O
Patients/O whose/O baseline/O ALT/O or/O AST/O were/O elevated/O were/O more/O likely/O to/O experience/O liver/B-AdverseReaction test/I-AdverseReaction elevation/I-AdverseReaction than/O those/O beginning/O with/O normal/O values/O ./O
Treatment/O discontinuation/O due/O to/O liver/B-AdverseReaction enzyme/I-AdverseReaction increases/I-AdverseReaction occurred/O in/O 1/O %/O of/O patients/O taking/O ZYTIGA/O ./O
No/B-Negation deaths/B-AdverseReaction clearly/O related/O to/O ZYTIGA/O were/O reported/O due/O to/O hepatotoxicity/B-AdverseReaction events/O ./O
Measure/O serum/O transaminases/O (/O ALT/O and/O AST/O )/O and/O bilirubin/O levels/O prior/O to/O starting/O treatment/O with/O ZYTIGA/O ,/O every/O two/O weeks/O for/O the/O first/O three/O months/O of/O treatment/O and/O monthly/O thereafter/O ./O
In/O patients/O with/O baseline/O moderate/O hepatic/O impairment/O receiving/O a/O reduced/O ZYTIGA/O dose/O of/O 250/O mg/O ,/O measure/O ALT/O ,/O AST/O ,/O and/O bilirubin/O prior/O to/O the/O start/O of/O treatment/O ,/O every/O week/O for/O the/O first/O month/O ,/O every/O two/O weeks/O for/O the/O following/O two/O months/O of/O treatment/O and/O monthly/O thereafter/O ./O
Promptly/O measure/O serum/O total/O bilirubin/O ,/O AST/O ,/O and/O ALT/O if/O clinical/O symptoms/O or/O signs/O suggestive/O of/O hepatotoxicity/O develop/O ./O
Elevations/O of/O AST/O ,/O ALT/O ,/O or/O bilirubin/O from/O the/O patient/O 's/O baseline/O should/O prompt/O more/O frequent/O monitoring/O ./O
If/O at/O any/O time/O AST/O or/O ALT/O rise/O above/O five/O times/O the/O ULN/O ,/O or/O the/O bilirubin/O rises/O above/O three/O times/O the/O ULN/O ,/O interrupt/O ZYTIGA/O treatment/O and/O closely/O monitor/O liver/O function/O ./O
Re/O -/O treatment/O with/O ZYTIGA/O at/O a/O reduced/O dose/O level/O may/O take/O place/O only/O after/O return/O of/O liver/O function/O tests/O to/O the/O patient/O 's/O baseline/O or/O to/O AST/O and/O ALT/O less/O than/O or/O equal/O to/O 2.5/O ULN/O and/O total/O bilirubin/O less/O than/O or/O equal/O to/O 1.5/O ULN/O [/O seeDosage/O and/O Administration/O (/O 2.2/O )/O ]/O ./O
The/O safety/O of/O ZYTIGA/O re/O -/O treatment/O of/O patients/O who/O develop/O AST/O or/O ALT/O greater/O than/O or/O equal/O to/O 20/O ULN/O and/or/O bilirubin/O greater/O than/O or/O equal/O to/O 10/O ULN/O is/O unknown/O ./O
